NX-0479

Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress Sept. 17, 2025 -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing research collaboration with Gilead Sciences. The findings support advancement of GS-6791 into clinical studies and are being presented at the European Academy of Dermatology and Venereology (EADV) Congress, taking place September 17–20, 2025, in Paris, France. The data show that GS-6791 mediates sustained degradation of IRAK4, resulting in robust inhibition of IL-1- and IL-36-driven responses in skin epithelial cell systems and significant disease reduction in a preclinical model of atopic dermatitis (AD). “As a potent, orally available degrader of the IRAK4 kinase, GS-6791 has a differentiated pharmacologic profile, providing an alternative method to target IRAK4 pathway with the potential to deliver efficacy in multiple inflammatory indications,” said Gwenn M. Hansen, Ph.D., chief scientific officer at Nurix. “These findings underscore the opportunity for targeted protein degradation to address complex immune signaling pathways and expand treatment possibilities for patients with inflammatory diseases.” “Our collaboration with Gilead has been highly productive, and we are excited to see the first program from this partnership advance into the clinic,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “These results highlight the potential of IRAK4 degradation as a novel approach for treating inflammation and autoimmune diseases and reinforce our shared commitment to developing innovative therapies that can improve outcomes for patients.” GS-6791 is designed to selectively degrade IRAK4, a signaling protein with both kinase and scaffold functions that plays a central role in toll-like receptor (TLR) and interleukin-1 family receptor (IL-1R) pathways. By degrading IRAK4, GS-6791 offers a differentiated mechanism of action compared to kinase inhibition alone. Preclinical data presented at EADV demonstrate that GS-6791 is a potent, selective, oral IRAK4 degrader with activity across immune and epithelial systems relevant to dermatologic disease: Potent IRAK4 degradation: Achieved near-complete knockdown in human blood and keratinocytes. Deep cytokine pathway inhibition: Potency against IL-1 and IL-36 signaling. Dermatology relevance: Reduced proinflammatory cytokines (IL-8, CXCL1, TSLP, IP-10) and disease-associated gene expression (DEFB4B, S100 family) in keratinocytes and 3D reconstructed human epidermis. In vivo efficacy: Suppressed cytokines in an IL-1β challenge model; reduced skin inflammation and improved barrier function in a mouse dermatitis model. Gilead exercised its option to license GS-6791 in March 2023, after which Gilead became responsible for all further development. The Investigational New Drug (IND) application for GS-6791 was cleared by the U.S. Food and Drug Administration (FDA) in April 2025. The ongoing Phase 1 clinical trial is evaluating the safety, tolerability, and pharmacodynamics of GS-6791 following single and multiple doses in healthy volunteers, including biomarker assessment in the skin. In June 2019, Gilead and Nurix entered into a global strategic collaboration to discover, develop and commercialize a pipeline of up to five innovative targeted protein degradation therapies for patients with cancer and other challenging diseases. To date, Nurix has received a total of $135 million under the terms of the agreement, and for the IRAK4 program, Nurix remains eligible for $420 million in potential clinical, regulatory, and commercial milestones payments as well as up to low double-digit tiered royalties on net sales. Nurix retains the option to co-develop and co-detail up to two programs in the United States, following completion of an applicable Phase 1 clinical trial, subject to certain restrictions. For those programs that Nurix opts in to co-develop and co-detail, the parties will split development costs as well as profits and losses 50/50 for the United States, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments. Gilead has the right to veto up to one co-development option, in which case the option will revert back to Nurix for use on potential future licensed products. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, a clinical stage degrader of IRAK4, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. The content above comes from the network. if any infringement, please contact us to modify.